PARLIAMENTARY WRITTEN QUESTION
Antimicrobials: Drug Resistance (7 March 2024)

A cross-Government, United Kingdom-wide delivery board monitors and oversees progress in delivering the National Action Plan on antimicrobial resistance (NAP AMR) for 2019 to 2024. The majority of the commitments in the NAP AMR have been assessed as either completed, or as on track for delivery.

Progress against the measurable ambitions in the NAP AMR is collated by the UK Health Security Agency, and reported to the delivery board. Significant progress has been made in further reducing antibiotic use in food producing animals, by 59% since 2014, and in humans, with an 8.8% reduction in overall antibiotic usage from 2014 to 2022. Progress has been slower in other areas, such as reducing the incidence of specific drug-resistant infections, due to the diverse nature of the underlying causes of these infections. Other key achievements from the NAP AMR programme over the past five years include:

- Piloting innovative ways of evaluating and paying for antibiotics on the National Health Service;

- Securing antimicrobial resistance commitments on several ministerial tracks during the UK G7 presidency in 2021; and

- £19.2 million investment into One Health Surveillance through the Pathogen Surveillance in Agriculture, Food and Environment Programme.

The Department has commissioned the Policy Innovation and Evaluation Research Unit (PIRU) at the London School of Hygiene and Tropical Medicine to conduct an evaluation of the 2019 to 2024 NAP AMR, to inform future policy development and implementation. Findings from the PIRU evaluation will be published following the peer-review process.

The forthcoming NAP AMR for 2024 to 2029 is under development, in consultation with a broad range of stakeholders across different sectors, and informed by the findings from the antimicrobial resistance Call for Evidence. This will set us on course for achieving our long-term ambitions, set out in the Government’s 20-year vision to contain, control, and mitigate antimicrobial resistance by 2040.